HCL001 cell therapy for advanced liver cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new cell injection called HCL001 for people with decompensated cirrhosis (advanced liver scarring causing complications). The goal is to see if it's safe and helps improve liver function. It may be an option if you've tried standard treatments and meet specific health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your liver cirrhosis is caused by hepatitis B or C, alcohol, autoimmune disease, fatty liver disease, or another accepted cause.
- You are well enough to perform daily activities (Karnofsky score 60 or higher).
- You have a blood vessel that can safely reach your liver's main artery.
- If you have hepatitis B or C, your virus levels must be very low or undetectable. If alcohol-related, you must have stopped drinking for at least 6 months.
- You are not pregnant, don't have active cancer, severe bleeding risk, or other major organ failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental liver cell injection to see if it is safe and can help people with decompensated cirrhosis, a serious liver condition. If you qualify, you may receive this new treatment to potentially improve liver function.
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
This trial tests whether giving a medicine that helps the body make more blood cells (called GCSF and darbepoetin) either once or a few times can help people with early liver failure (decompensated cirrhosis). The goal is to see if it helps the liver work better and improve the patient's health.
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
This study tests an injection called CUD005 for people with advanced liver cirrhosis that is causing complications. The goal is to see if it is safe and can help improve liver function.
This trial tests an injection of stem cells from donated umbilical cords to see if it can help people with advanced liver scarring from hepatitis B. You may be able to join if standard treatments haven’t helped enough and you aren’t able to get a liver transplant.
Hear when a new Decompensated Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.